Targeted Ocular Drug Delivery with Pharmacokinetic/Pharmacodynamic Considerations

被引:34
|
作者
Shen, Jie [1 ]
Lu, Guang Wei [2 ]
Hughes, Patrick [3 ]
机构
[1] Allergan Plc, Clin Pharmacol Nonclin & Translat Sci, 2525 Dupont Dr, Irvine, CA 92612 USA
[2] TWi Pharmaceut Inc, Ophthalm Prod Dev, Taipei, Taiwan
[3] Glaukos Corp, Appl Res, San Clemente, CA USA
关键词
formulation; ocular; pharmacokinetic; pharmacodynamic; sustained release; targeted delivery; EPISCLERAL CYCLOSPORINE IMPLANT; IN-VITRO; SUBCONJUNCTIVAL BEVACIZUMAB; SUSTAINED-RELEASE; VIVO EVALUATION; AQUEOUS-HUMOR; GLAUCOMA; PHARMACOKINETICS; LATANOPROST; ABSORPTION;
D O I
10.1007/s11095-018-2498-y
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The development of ophthalmic drug delivery systems is a long and comprehensive process including research, nonclinical, and clinical development stages. It is critical to understand the similarity and differences between animal models and patients. There are many anatomically and physiologically important parameters for targeted drug delivery into eyes. This paper reviews the constraints to various routes of ocular drug delivery and discusses the respective pharmacokinetic considerations, to lay the foundation for formulation approaches pharmaceutical scientists can use to maximize successful drug delivery for each route. The overall goal is to give both researchers and drug developers a better understanding of ocular drug delivery and offer tools to successfully develop new medicines that will fulfil unmet medical needs and improve patients' quality of life.
引用
收藏
页数:20
相关论文
共 50 条
  • [21] Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics
    Dhaval K. Shah
    Journal of Pharmacokinetics and Pharmacodynamics, 2015, 42 : 553 - 571
  • [22] PHARMACOKINETIC AND PHARMACODYNAMIC BASIS FOR PEPTIDE DRUG DELIVERY SYSTEM-DESIGN
    BREIMER, DD
    JOURNAL OF CONTROLLED RELEASE, 1992, 21 (1-3) : 5 - 10
  • [23] Ocular Drug Delivery: a Comprehensive Review
    Ahmed, Sadek
    Amin, Maha M.
    Sayed, Sinar
    AAPS PHARMSCITECH, 2023, 24 (02)
  • [24] Key considerations based on pharmacokinetic/pharmacodynamic in the design of antibody-drug conjugates
    Gao, Yangyang
    Xia, Yuwei
    Chen, Yixin
    Zhou, Shiqi
    Fang, Yingying
    Yu, Jieru
    Zhang, Leyin
    Sun, Leitao
    FRONTIERS IN ONCOLOGY, 2025, 14
  • [25] Microprocessor-controlled iontophoretic drug delivery of 5-fluorouracil: pharmacodynamic and pharmacokinetic study
    Chandrashekar, N. S.
    Ran, R. H. Shobha
    JOURNAL OF BUON, 2007, 12 (04): : 529 - 534
  • [26] Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations
    Stott, Katharine E.
    Hope, William W.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017, 72 : I12 - I18
  • [27] Drug-Drug Interaction Studies With Oral Contraceptives: Pharmacokinetic/Pharmacodynamic and Study Design Considerations
    Sun, Haiying
    Sivasubramanian, Rama
    Vaidya, Soniya
    Barve, Avantika
    Jarugula, Venkateswar
    JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 60 : S49 - S62
  • [28] Electrospun formulations of acyclovir, ciprofloxacin and cyanocobalamin for ocular drug delivery
    Baskakova, Alexandra
    Awwad, Sahar
    Jimenez, Jennifer Quiros
    Gill, Hardyal
    Novikov, Oleg
    Khaw, Peng T.
    Brocchini, Steve
    Zhilyakova, Elena
    Williams, Gareth R.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2016, 502 (1-2) : 208 - 218
  • [29] Pharmacodynamic and pharmacokinetic drug interactions
    Pleuvry, Barbara J.
    ANAESTHESIA AND INTENSIVE CARE MEDICINE, 2005, 6 (04) : 129 - +
  • [30] Novel drug delivery systems for ocular therapy: With special reference to liposomal ocular delivery
    Bhattacharjee, Arpita
    Das, Pranab J.
    Adhikari, Piya
    Marbaniang, Daphisha
    Pal, Paulami
    Ray, Subhabrata
    Mazumder, Bhaskar
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2019, 29 (01) : 113 - 126